Diffuse gliomas represent a heterogeneous group of universally lethal brain tumors
characterized by minimally effective genotype-targeted therapies. Recent advances have …

Lung cancer is the leading cause of cancer mortality. It is classified into different histologic
subtypes, including adenocarcinoma, squamous carcinoma, and large cell carcinoma …

Activated EGFR signalling drives tumorigenicity in 50% of glioblastoma (GBM). However,
EGFR-targeting therapy has proven ineffective in treating patients with GBM, indicating that …

The epidermal growth factor receptor (EGFR) is a receptor tyrosine kinase that is commonly
upregulated in cancers such as in non-small-cell lung cancer, metastatic colorectal cancer …

Receptor tyrosine kinases (RTKs) play an important role in a variety of cellular processes
including growth, motility, differentiation, and metabolism. As such, dysregulation of RTK …

Recent advances in genomic technology have led to a better understanding of key
molecular alterations that underlie glioblastoma (GBM). The current WHO-based …

Cancer is currently the second leading cause of death globally and is expected to be
responsible for approximately 9.6 million deaths in 2018. With an unprecedented …

The ligand-stimulated epidermal growth factor receptor (EGFR) has been extensively
studied in the analysis of molecular mechanisms regulating endocytic traffic and the role of …

Patients with glioblastoma (GBM) have a universally poor prognosis and are in urgent need
of effective treatment strategies. Recent advances in sequencing techniques unraveled the …

Recent structural studies of receptor tyrosine kinases (RTKs) have revealed unexpected
diversity in the mechanisms of their activation by growth factor ligands. Strategies for …